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Abstract
In South Carolina, mortality differences between African American (AA) and Caucasian-American
(CA) women with breast cancer are amongst the highest in the country. Increasing evidence
suggests that the racial disparity exists independent of socioeconomic and standard of care
issues and could also be attributed to poorly understood inherent genetic and molecular
characteristics within racial specific tumors. Caveolin-1 (Cav1) is a scaffolding protein with a
tumor suppressor role. Loss of Cav1 in the tumor stromal compartment has emerged as a novel
biomarker for predicting poor clinical outcome in all of the most common subtypes of breast
cancer. While the loss of stromal Cav1 is becoming well established as a marker of poor
outcome in breast cancer, the mechanism of this loss is still unknown. We propose that
differences in microRNA mediated stromal Cav1 loss between AA and CA women are driving the
racial disparity in breast cancer. MicroRNAs (miRNAs) are short, endogenous, non-coding RNAs
that function as negative regulators of gene expression. miR-510 is an oncogenic miRNA that has
been shown to be elevated in breast tumors. Cav1 is a predicted target of miR-510; therefore,
miR-510 mediated negative regulation may be a novel mechanism of Cav1 loss in the tumor
stroma. Our research shows that Cav1 is directly targeted by miR-510 by luciferase reporter
assay and that overexpression of miR-510 leads to downregulation of Cav1 protein expression,
specifically in the stromal compartment. This may be racially significant as our supporting
studies also show that miR-510 levels are elevated and Cav1 levels are reduced in AA breast
cancer patients compared to their CA counterparts. Data from our in vivo studies shows that
tumors grown from co-injection of MDA-MB-231 cells plus miR-510 derived fibroblasts resulted
in faster tumor growth and larger tumors at the end of the study than tumors grown from
injection of MDA-MB-231 cells alone, suggesting that miR-510 derived fibroblasts enhance
i

tumorigenicity when co-injected with breast tumor epithelial cells. Our results suggest that the
difference in miR-510 mediated regulation of stromal Cav1 is driving racial disparity in breast
cancer.
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Background/Review of Literature
Breast Cancer: Breast cancer is the most commonly diagnosed cancer in women. In 2015, an
estimated 231,840 new cases of invasive breast cancer are expected to be diagnosed in women
in the United States, with 60,290 new cases of non-invasive (in situ) breast cancer diagnosed.
Breast cancer is also the second-leading cause of death among women; in fact, 40,290 women in
the U.S are expected to die from the disease in 2015 [1]. A number of risk factors can contribute
to breast cancer development, including lifestyle, environmental, and genetic factors. Some
controllable risk factors include, diet, exercise, alcohol consumption, smoking and weight.
Evidence shows that women are more likely to develop breast cancer if they have poor diets low
in fresh fruits and vegetables, live primarily sedentary lifestyles lacking exercise, frequently
consume copious amounts of alcohol, use tobacco products, or are overweight [2]. Exposure to
estrogen through hormone replacement therapies and oral contraceptive use can also
contribute to cancer growth [2; 3]. Environmental factors, such as radiation exposure and
exposure to various pollutants and pesticides are also thought to increase risk [2; 3]. One of the
most evident genetic factors contributing to breast cancer development is gender. Although
men can also develop the disease, women are at a much higher risk due to the increased
prevalence and activity of progesterone and estrogen in their bodies. Risk even increases with
age; in fact, two out of three women with invasive cancer are diagnosed after age 55 [3]. A
personal history or family history of breast cancer, especially in the immediate family, also
increases the risk of developing the disease. Other personal risk factors can include an early
onset of menarche, a pregnancy later in age or no pregnancies at all, dense breast tissue, which
can make it more difficult to detect abnormalities, or late menopause [3]. Race is also a risk
factor associated with breast cancer, as Caucasian-American (CA) women are more likely to be
1

diagnosed with the disease, but African-American (AA) women suffer from higher mortality
rates [2]. While a variety of non-biological factors contribute to the development of breast
cancer and a racial disparity, this project focuses strictly on biological factors and seeks to
uncover a biological mechanistic link driving higher mortality rates in AA breast cancer patients,
as shown in Figure 1.
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Figure 1: Conceptual Model. Breast cancer
disparities are attributed to a combination of
sociodemographic factors and inherent biological
factors. Disparities also exist independently of
sociodemographic factors. Aim 1 of this project
examines a biological mechanism contributing to
breast cancer disparities, while Aim 2 examines
functional outcome of this mechanism.
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Mammary gland development mostly occurs postnatally, with cell differentiation taking place at
multiple stages, including pregnancy, lactation, and the involution cycle [4]. The mammary gland
is composed of multiple cell types that interact with each other and with the microenvironment
to facilitate proper development and function of the breast. The milk-transporting ducts are
lined by an inner layer of secretory luminal epithelial cells and are surrounded by myoepithelial
cells and the basement membrane [4]. These same cell-cell and cell-microenvironment
interactions that facilitate normal breast development are also subject to mutations and
abnormal epithelial proliferation that lead to breast tumorigenesis. Breast carcinomas most
often arise from the milk-producing lobules of the breast or from the milk-transporting ducts.
Abnormal cells contained in the lobules are known as lobular carcinoma in situ (LCIS), while
abnormal cells contained in the ducts are known as ductal carcinoma in situ (DCIS), as these
cancers have not yet infiltrated beyond the original cell layer. There are a number of
histopathological changes that occur during the progression of in situ to invasive breast
carcinoma and finally, metastasis [4]. Studies have shown that progression to invasive breast
carcinoma is promoted by stromal fibroblasts, whose numbers increase as the tumor
progresses, and is inhibited by normal myoepithelial cells, whose numbers decrease as the
tumor progresses, through their combined effects on the basement membrane [4; 5].

Breast Cancer Disparities: Significant racial disparities exist for African-American (AA) women
compared to Caucasian-American (CA) women, especially in our state of South Carolina. Studies
including data from SC residents with BC show that AA women exhibit more advanced stage,
more aggressive histologic features, and worse survival than their counterparts, even if detected
at earlier stages [6; 9]. In general, AA women develop breast cancer 5-10 years earlier than their
4

counterparts [7]. A study conducted in Columbia, SC determined that tumors from AA women
with BC in SC are significantly larger than in CA women at every decade of age [9]. Data from
this same study shows that ER negative status and high-grade, a highly unfavorable combination
for prognosis, is twice as common in AA women as in CA women in the state of SC [9]. According
to the American Cancer Society, CA women in the US have a greater incidence of breast cancer,
with 128.1 per 100,000 compared to AA women at 124.3 per 100,000 [Figure 2]. However, even
with a lower incidence, AA women are still more likely to die from the disease, with 31.0 deaths
per 100,000 compared to 21.9 deaths per 100,000 in CA women. Even more shocking than the
elevated mortality rate is the survival rate of AA women diagnosed with breast cancer.
According to the Center for Disease Control, the current 5-year relative survival rate is 77% for
AA women compared to 90% among CA women. Previous data also reveals that AA women have
a higher recurrence rate regardless of age and tumor size [8].

5

Figure 2: Breast cancer incidence and mortality rates by
race and ethnicity, 2008-2012. Adapted from ACS Breast
Cancer Facts and Figures 2015-2016.
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Biological Factors and Mechanisms in Cancer: While strong evidence exists linking non-biological
factors to racial disparities in breast cancer, studies show there is evidence for biological factors,
as well [Figure 1]. After adjusting for clinical, demographic, and treatment variables, does the
survival disparity still exist between AA and CA women? The Southwest Oncology Group (SWOG)
conducted a study of approximately 20,000 various cancer patients from 1974-2001 through 35
randomized phase III clinical trials. The patients were first grouped by cancers of similar
histology and stage, followed by an assessment of overall survival after controlling for
socioeconomic status, prognostic, and treatment variables. Interestingly, the study concluded
that even after controlling for these factors, AA patients had statistically significantly worse
survival in sex-specific cancers (breast, ovarian, and prostate), including both early stage
pre/postmenopausal breast cancer [10]. This data strongly suggests that inherent biological and
molecular characteristics are predisposing AA women to worse breast cancer survival outcomes
independent of standard of care issues. Genetic and molecular contributors are thought to
include hormonal factors, inherited single-nucleotide polymorphisms associated with
inflammatory processes, and communications between cell types in the mammary gland [9; 10].

The contribution of biological mechanisms promoting cancer disparities is not clear, thus the
study of these mechanisms remains a challenge. However, a few biological mechanistic links
have been identified in other sex-specific cancers, previously mentioned to have statistically
significant worse survival in AAs. AA prostate cancer patients exhibit more aggressive cancers
and higher mortality rates compared to CA prostate cancer patients [11-15]. Foster and
colleagues examined advanced glycation end product (AGE) metabolites in clinical specimens of
AA and CA prostate cancer patients. AGEs are reactive metabolites formed during glycation and
7

contribute to a number of diseases, including diabetes and cardiovascular disease [14; 15]. AGE
functions as a ligand activator for RAGE (receptor for AGE), which is an oncogenic
transmembrane receptor that promotes inflammatory responses [15]. Activation of the AGERAGE inflammation signaling axis promotes inflammation and contributes to tumorigenesis and
worse outcome in AA prostate cancer patients [14; 15]. In both low-grade and high-grade
serum, AA patients had significantly higher circulating AGE metabolite levels, which also showed
a strong positive correlation with AGE levels observed in the tumor [14]. This race specific,
tumor-dependent pattern of AGE accumulation represents a biological mechanistic link between
cell metabolism and cancer [14; 15].

Another racial disparity in both incidence and survival outcomes exists in AA vs. CA women for
endometrial cancer [16; 17]. Allard and colleagues identified a gene influencing this disparity
through transcript expression analysis in normal and tumor tissue samples from AA and CA
endometrial cancer patients [16]. Phospho serine phosphatase like (PSPHL) was found to be the
most differentially over-expressed gene in AA endometrial cancer patients, along with an
additional splice variant clone. Ultimately, PSPHL may be able to serve as a prognostic marker in
endometrial cancer, and its effect on biologic function requires further investigation.

Zhao and colleagues also identified a racial disparity in AA compared to CA women with early
breast cancer. This team performed miRNA expression analysis amongst these racial groups and
found that 31 miRNAs were significantly differentially expressed between CA cases and CA
healthy controls, and 18 miRNAs were significantly differentially expressed between AA cases
and AA healthy controls [18]. Interestingly, they only found two differentially expressed miRNAs
8

overlapping between CA and AA study subjects, suggesting potential racial differences in
circulating miRNA expression in early breast cancer patients.

MicroRNAs: MicroRNAs (miRNAs) are small, non-coding RNAs approximately 19-24 nucleotides
long that affect expression of protein-coding genes primarily through binding to the 3’ UTR of
their mRNA targets [31]. MiRNAs can regulate gene expression through translational repression
of their target genes or by degradation of the mRNA transcript [31]. Interestingly, one miRNA
has the ability to regulate expression of hundreds of genes, and a single transcript can be
targeted by multiple miRNAs [46]. They are also involved in a number of cellular and
physiological processes, including tissue development, cellular differentiation and proliferation,
signaling pathways, and apoptosis [32; 46]. Most miRNAs reside between genes (intergenic) and
are transcribed as primary miRNA (pri-miRNA) transcripts by RNA polymerase II. miRNAs can
also reside within introns of protein coding or non-protein coding genes (intronic) and must be
excised through splicing [47]. The biogenesis of miRNAs begins in the nucleus, where miRNAs
are transcribed by RNA polymerase II or RNA polymerase III to produce the pri-miRNA transcript.
The pri-miRNA is then cleaved by the Microprocessor, which includes Drosha and DGCR8,
resulting in the precursor miRNA (pre-miRNA) hairpin. The pre-miRNA is exported out of the
nucleus by Exportin 5 to be further processed by the Dicer complex. Dicer cleaves the loop, and
one strand of the miRNA duplex is loaded onto Argonaute to form the miRNA-RISC complex. The
now mature miRNA is then capable of down-regulating gene expression through mRNA decay or
translation inhibition [Figure 3].
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Figure 3: microRNA biogenesis.
Adapted from Joshi, et al 2011.
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Mounting evidence indicates that miRNAs also play a role in carcinogenesis acting either as
oncogenes or tumor suppressors [31; 32; 46; 48]. About 50% of annotated human miRNAs are
detected in cancer associated regions and fragile sites [32; 48], with 72.8% of breast cancers
exhibiting miRNA abnormalities [49]. Recently, it was discovered that extracellular miRNAs
circulate in the blood of both healthy and diseased patients, and they are both stable and
detectable in human serum and plasma [48; 50]. This allows miRNAs to be measured repeatedly
and non-invasively and has sparked extensive research in miRNAs as therapeutic targets, as well
as potential biomarkers of prognosis and diagnosis. MiRNA secretion and its role in intercellular
communication have also recently gained increased attention. Studies have provided evidence
that microvesicles (up to 1 µm) released from many cell types can transfer miRNAs to
neighboring or distant cells, and these exogenous miRNAs function similarly to endogenous
miRNAs to regulate target gene expression and recipient cell function [48; 50; 51]. Therefore,
secreted miRNAs may serve as a novel class of signaling molecules for mediating cell-to-cell
communication.

miR-510: MiR-510, the miRNA of interest in this study [Figure 1], is located in the intergenic
region of chromosome Xq27.3, a region that is reported to be amplified in cancer [54]. While
few studies have investigated miR-510 in cancer, our lab has shown that miR-510 levels are
significantly elevated in breast cancer samples compared to matched non-tumor samples [31].
Furthermore, our published studies have shown that over-expression of miR-510 in the noninvasive MCF7 breast cancer cell line results in increased migration, invasion, and colony
formation in soft agar and a morphology change similar to that observed in cells undergoing
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EMT [52]. Further research is necessary to investigate the role of miR-510 in the development
and progression of breast cancer.

MiR-510 has also been shown to act as a prognostic marker in ovarian cancer, another sexspecific cancer previously mentioned to be disparate after controlling for socioeconomic status,
prognostic, and treatment variables. Zhang and colleagues concluded that the expression of
miR-510 was significantly higher in low grade serous carcinoma and clear cell carcinoma tissues,
compared with high grade serous carcinoma and normal ovarian tissues [53]. Therefore, miR510 may potentially serve as a novel biomarker for clinical outcome prediction in epithelial
ovarian cancer.

Caveolin-1: Our lab chose to examine Caveolin-1 protein and its relationship with miR-510
[Figure 1], because considerable amounts of literature show that Caveolin-1 expression has
prognostic significance specifically in breast cancer [35; 37; 38; 39; 40; 41]. Caveolin-1 (Cav-1) is
a membrane-bound scaffolding protein and the structural/functional element of Caveolae.
Caveolae are small invaginations of the plasma membrane about 50-100 nm in diameter, and
they serve as signaling regulators for a variety of pathways [33]. Cav-1 is a homo-dimer that
enables anchorage to the plasma membrane through a central hydrophobic domain, which is
flanked by hydrophilic N- and C-terminal cytosolic domains [35]. Cav-1 is thought to play a role
in tumorigenesis through various functions, including lipid transport, membrane trafficking,
gene regulation, and signal transduction [36]. Located on the cell surface in most cell types, Cav1 expression is most abundant in terminally differentiated cells such as epithelial and
endothelial cells, fibroblasts and adipocytes [33; 34]. Terminally differentiated cells are often
12

regulated by pathways that act to prevent cell-cycle progression; therefore, abundant Cav-1
expression in these cell types suggests that Cav-1 acts as a tumor suppressor by regulating
pathways involved in cell-cycle progression, such as the RB/E2F pathway [24; 44]. This data is
further supported by studies that have shown that Cav-1 negatively regulates cell proliferation
(i.e. inhibition of pro-proliferative signaling pathways initiated by receptor tyrosine kinases or
serine-threonine protein kinases [44]), exhibiting another role of tumor suppression [34; 38].
The Cav-1 gene, CAV1, maps to a suspected tumor suppressor locus (D7S522/7q31.1) that is
frequently deleted in a number of carcinomas, including breast cancers [33].

Cav-1 in Breast Cancer: Cav-1 expression in the stromal compartment is a strong predictor of
clinical outcome in breast cancer patients [38]. Ductal carcinoma in situ (DCIS) that exhibit loss
of stromal Cav-1 are more likely to progress to invasive carcinomas, suggesting that Cav-1 loss
regulates tumor progression [39]. Numerous studies have demonstrated that loss of stromal
Cav-1 is significantly associated with larger tumor size, higher grade, higher nodal stage, higher
recurrence rate, metastasis, and reduced progression-free survival [35; 38]. Overall, breast
cancer patients with a loss of stromal Cav-1 show a 20% 5-year survival rate, compared to the
80% 5-year survival of patients with high stromal Cav-1 expression [40]. Interestingly,
researchers have also shown that positive expression of stromal Cav-1 is associated with
improved outcome in breast cancer, including a higher survival rate [37; 38; 41]. While strong
evidence exists showing the significance of stromal Cav-1 loss in breast cancer outcome, it is
important to note that there is no known association between Cav-1 expression in the epithelial
compartment and clinical outcome [35; 37; 38; 41].
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The effects of Cav-1 loss have been studied extensively utilizing in vivo models. A study by
Williams and colleagues showed that loss of Cav-1 expression accelerates the development of
dysplastic mammary lesions in tumor-prone transgenic mice [42]. Polyomavirus middle T
antigen transgenic mice (PyMT) provide an ideal model to study the effect of a given gene on
early tumorigenesis, because multifocal dysplastic foci develop in the mammary epithelium of
PyMT mice as early as 3 weeks of age. Figure 4 shows identical magnifications of Cav-1 positive
mice and Cav-1 null mice at 3 weeks, carmine-stained and whole mounted. The primary duct
(PD), which originates from the nipple area, is visible in the top left corner and terminal end
buds (TEB) are also visible. What is important to note is the dramatically increased size and
number of the dysplastic foci in the mammary glands of Cav-1 null mice compared to the Cav-1
positive mice. At 4 weeks, the mammary epithelial tree extended to the region of the lymph
node in both genotypes, and the dysplastic areas in the mammary glands of Cav-1 null mice
coalesced to form larger singular masses [42].

Figure 4: Foci development in mammary glands of
tumor-prone transgenic mice at 3 weeks of age,
carmine-stained and whole mounted. Adapted
from Williams, et al 2003.
14

Tumor Microenvironment: The tumor microenvironment is the stroma hosting malignant breast
cancer cells, which includes the extracellular matrix (ECM) and various stromal cell types:
leukocytes, fibroblasts, myoepithelial cells, and endothelial cells [4;19]. The tumor stroma
changes during malignancy and eventually promotes growth, invasion, and metastasis.
Specifically, we see infiltration of inflammatory cells, angiogenesis, and ECM remodeling [21].
Studies show that the cellular microenvironment is dramatically different at the molecular level
between normal breast tissue and breast carcinomas, with differences already evident at the in
situ stage before invasion even takes place [4; 5; 18; 20]. In DCIS, myoepithelial cells are
phenotypically altered and their numbers decreased [Figure 5]. As breast cancer progresses, the
number of stromal fibroblasts increases, as well as numbers of myofibroblasts, lymphocytes,
and endothelial cells [4; 21].

Figure 5: Micro environmental alteration during tumor
progression. Adapted from Polyak K & Kalluri R 2010.
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Cancer-Associated Fibroblasts: Down-regulation of Cav-1 is a mechanism implicated in the
oncogenic transformation of fibroblasts to cancer-associated fibroblasts (CAFs) [37; 42]. One of
the most prominent cell types in the tumor stroma is the activated fibroblast, or CAF. Normal
fibroblasts are responsible for the development of most of the connective tissue components
and the synthesis and turnover of the ECM [22; 23; 25]. In addition, they control tissue
homeostasis and actively participate in wound healing and senescence [23; 25]. But unlike
normal fibroblasts, CAFs inhabit the tumor itself or infiltrate the tumor mass, and promote
tumor progression by encouraging tumor growth, inflammation, and metastasis through various
mechanisms [21; 23; 25]. CAFs can promote tumor growth through release of growth factors,
such as hepatocyte growth factor (HGF) and transforming growth factor beta (TGF-β), or
vascularization through vascular endothelial growth factor (VEGF) [21]. They can also promote
tumor invasion through modulation of matrix metalloproteinase (MMP) activity, metastasis by
inducing epithelial-to-mesenchymal transition (EMT), and prevent cancer cell apoptosis [19; 25;
30]. In co-culture experiments, CAFs have been shown to enhance proliferation and migration,
while in vivo studies have demonstrated their ability to promote angiogenesis [23; 24]. CAFs are
also said to be perpetually activated, as they never revert to a normal phenotype or undergo
apoptosis or spontaneous quiescence as would a wound-healing fibroblast [24; 26]. Although
many plausible sources of CAFs have been identified by researchers, they can be viewed as
normal fibroblasts altered by continuous exposure to cancer cells that promote tumorigenesis
[Figure 1].

Epithelial-stromal Crosstalk: Epithelial-stromal communication though the ECM is crucial for
proper development and function of the mammary gland. However, disruption of the cell-cell
16

interactions between compartments can both induce and promote breast cancer [19; 27; 28].
Evidence has demonstrated that compared to normal mammary gland stroma, the tumor
microenvironment shows disruption of epithelial-fibroblast cell communication in terms of cell
proliferation and extracellular matrix remodeling [2; 30]. While studies show that the mammary
stroma provides instructive and permissive signals that allow the mammary epithelium to
proliferate and invade, oncogenic signaling occurs reciprocally and creates advantageous
conditions for malignant cells [22; 27].
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Hypothesis: miRNAs secreted from epithelial tumor cells to nearby stromal cells is a mechanism
leading to Cav-1 reduction, resulting in increased levels of cancer-associated fibroblasts in the
tumor microenvironment, and thereby promoting tumor progression and worse outcome in AA
breast cancer patients [Figure 1].
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Specific Aim 1: To assess whether miR-510 expression in epithelial cells results in the
reduction of Cav-1 in fibroblasts in vitro.
Rationale: There is a well-established correlation between reduced stromal Cav-1 expression
and outcome in breast cancer patients; however, the mechanism of loss is still unclear.
Accumulating evidence has demonstrated that interactions between malignant epithelial cells
and stromal fibroblasts contribute to tumor initiation and progression [28]. The two
compartments communicate through release of various soluble factors to create advantageous
conditions for the tumor microenvironment [22; 28]. A proposed mechanism of this epithelialstromal communication is tumor-derived microvesicles, shown to be released from epithelial
tumor cells [28; 51]. These microvesicles serve as intercellular transmitters, capable of carrying
miRNA, mRNA, proteins, DNA, and lipids [50; 51; 55]. Once assimilated by cells of the tumor
microenvironment, the contents of these vesicles may modulate the molecular profile and
function of recipient cells, leading to tumorigenesis [55]. Specifically, miRNAs have been shown
to be transferable by microvesicles, such as exosomes, and functional in recipient cells [50; 51].
miRNA target prediction software (TargetScan) predicted Cav-1 to be a direct target of miR-510.
Therefore, this aim will first establish Cav-1 as a novel direct target of miR-510 and then will
explore the possibility that miR-510 secreted from epithelial cells in microvesicles negatively
regulates Cav-1 expression in neighboring stromal cells.

19

Preliminary Data
miR-510 levels are elevated in human breast cancer patients. Previous work in our lab has shown
miR-510 to be significantly elevated in human breast tumor samples compared to matched nontumor samples, suggesting an important role in breast cancer progression within an individual
patient [Figure 6A]. Preliminary experiments in the lab also investigated the potential disparate
expression of miR-510 by examining serum samples of AA and CA women. Analysis of serum
miR-510 was performed utilizing qPCR, and the results show a statistically significant increase of
miR-510 in the serum of AA women with BC when compared to AA women with benign disease
[Figure 6B]. However, this increase in serum miR-510 levels was not significant in CA women
with BC compared to benign disease. We also observed a trend in the elevation of miR-510
levels in the serum of AA women with BC compared to CA women with BC however due to the
small sample size this did not reach statistical significance. The trends we observed suggests
miR-510 may be elevated in AA women with BC. This will have to be further confirmed in a large
scale study, but it does provide evidence that miR-510 expression may be racially disparate.

20

Figure 6: miR-510 expression in breast cancer
patient samples. qPCR assessing normalized miR510 expression in breast tumors compared to
matched non-tumor samples (A). qPCR
quantitation of miR-510 expression in serum of
CA vs. AA women with breast cancer (B).
(****CA-Benign v. CA-Cancer = .29 *** CACancer v. AA-Cancer = .12 ** AA-Benign v. AACancer = .04 *AA-Benign v. CA-Benign = .40)
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Cav-1 levels are disparate in AA breast and prostate cancer patients. Data mining revealed that
Cav-1 mRNA levels are lower in AA women with breast cancer (tumor epithelial or stromal not
specified) when compared to CA women in data sets from Oncomine [Figure 7A]. These findings
suggest loss of stromal Cav-1 may be the mechanism leading to poorer breast cancer survival in
AA women and warrants further investigation of its role in promoting breast cancer disparity.
Clinical studies suggest that AA prostate cancer patients manifest a more aggressive form of the
disease compared with CA prostate cancer patients. Cav-1 IHC from this study shows that Cav-1
levels are elevated in the stroma of white patients, while levels are elevated in the epithelial
cells of AA patients [Figure 7B]. Subsequent studies have shown an inverse correlation between
epithelial and stromal expression, suggesting perhaps that stromal Cav-1 is lower in AA prostate
patients, which leads to a poorer outcome [45].

22

Figure 7: Cav-1 levels are disparate in AA breast and prostate cancer
patients. Cav-1 mRNA expression is lower in AA women compared to
CA women with breast cancer. Adapted from Chang Data Set,
Oncomine (A). Cav-1 IHC shows that Cav-1 levels are elevated in the
stroma of CA prostate cancer patients, while levels are elevated in the
epithelial cells of AA patients. Adapted from Yang, et al 2011 (B).
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Specific Aim 1 Tasks:
Task 1: Perform miR-510 gain of function (GOF) studies in cell lines to define:


If miR-510 overexpression correlates with loss of Cav-1 protein/mRNA expression in
MDA-MB-231 tumor epithelial cells



If miR-510 overexpression correlates with loss of Cav-1 protein/mRNA expression in
WPMY1 stromal fibroblasts

Task 2: Clone the 3’UTR of Cav-1 in luciferase reporter vector
Task 3: Perform dual luciferase assay to determine:


If Cav-1 mRNA is a direct target of miR-510

Task 4: Perform site directed mutagenesis to mutate the seed site for miR-510 in Cav1 3’UTR
Task 5: Perform dual luciferase assay to determine:


If miR-510 directly targets CAV1 3’UTR through the predicted site

Task 6: Perform in vitro co-culture studies with MDA-MB-231 tumor epithelial cells and WPMY1
stromal fibroblasts to determine:


If miR-510 is secreted from MDA-MB-231 epithelial cells



If miR-510 is taken up by WPMY1 stromal fibroblasts when cultured together with MDAMB-231 tumor epithelial cells



If transfer of miR-510 from MDA-MB-231 tumor epithelial cells results in a loss of Cav-1
in the WPMY1 stromal fibroblasts

Task 7: Perform migration assay in co-cultured WPMY1 stromal fibroblasts to determine:


If WPMY1 stromal fibroblasts co-cultured with miR-510-expressing MDA-MB-231 tumor
epithelial cells are more aggressive compared to those co-cultured with a scrambled
control expressing MDA-MB-231 tumor epithelial cells.
24

Task 8: Perform exosome isolation from in vitro co-culture studies to determine:


If MDA-MB-231 tumor epithelial cells transfer miR-510 into neighboring WPMY1 stromal
fibroblasts via exosomes

25

Specific Aim 1 Methods:
Cell Culture: MDA-MB-231 and MCF10a breast epithelial cell lines, as well as NIH-3T3 mouse
stromal cells, were utilized for miR-510 overexpression. WPMY1 prostate stromal cells were
also utilized for miR-510 overexpression in lieu of a primary breast stromal cell line. HEK-293 cell
lines were utilized for the dual luciferase assay. All cell lines were cultured in a 37°C, 5% CO2
incubator in their respective media. MDA-MB-231, 3T3, WPMY1, and HEK-293 cells were
incubated in DMEM/High Glucose media (HyClone, South Logan, UT), with 10% fetal bovine
serum (FBS) (HyClone, South Logan, UT) and 1% Penicillin/Streptomycin mixture (Fisher
Scientific, Hampton, NH). MCF10a cells were incubated in DMEM/F media (HyClone, South
Logan, UT), with 10% fetal bovine serum (FBS) (HyClone, South Logan, UT) and 1%
Penicillin/Streptomycin mixture (Fisher Scientific, Hampton, NH). Media on the cells were
changed every 2-3 days and cells are passaged by using 0.05% trypsin (HyClone, South Logan,
UT) when plates were ≤90% confluent.

GOF studies: MDA-MB-231 and MCF10a epithelial cells, as well as NIH-3T3 and WPMY1 stromal
fibroblasts are plated at a density of 1 x 105 cells/mL in 2ml in a 6 well plate. After 24 hours, the
cells are transfected with 200 µL of OPTI-MEM, either 1µg pEZX Scr vector (control), 0.5µg or
1µg pEZX miR-510 vector, and 3 µL of XTREME Gene HP DNA Transfection Reagent per µg of
DNA, followed by a 15 minute incubation period. After 48 hours, the cells are collected for RNA
and protein extraction.

Quantitative Real Time PCR (qPCR), Reverse Transcription and downstream analysis: RNA is
extracted using the RNeasyPlus Mini Kit from Qiagen as per the manufacturer’s instructions. For
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microRNA analysis, 100 ng total RNA is reverse transcribed using miR-510 specific primers using
the Applied Biosystems reverse transcription kit as per the manufacturer's instructions. qPCR is
performed with 1 µl of reverse transcribed cDNA using the TaqMan Assay from Applied
Biosystems as per the manufacturer's instructions on the Roche LightCycler 480. For mRNA
analysis, 1 µg total RNA is reverse transcribed in a 20 µl reaction using iScript (Bio-Rad). qPCR for
gene expression is performed with 5 µl of a 1:20 dilution of reverse transcribed cDNA using the
universal probe library (UPL) system from Roche (Nutley, NJ) in a LightCycler (see Table 1). The
cycling conditions are performed as per the manufacturer's instructions. Triplicate reactions are
run for each cDNA sample. The relative expression of each gene is quantified on the basis of Ct
value measured against an internal standard curve for each specific set of primers using the
software provided by the instrument manufacturer (Roche, Nutley, NJ). The data is normalized
to GAPDH.

Table 1: iScript (BioRad) Genes and UPL System Data
Gene

UPL Number

5’ Primer Sequence

3 Primer Sequence

Amplicon
Length

CAV1

60

acagcccagggaaacctc

ggatgggaacggtgtagagat

103 nt

COLLAGEN1

50

caggcaaacctggtgaaca

ctcgccagggaaacctct

89 nt

EPCAM

3

ccatgtgctggtgtgtgaa

tgtgttttagttcaatgatgatcca

111 nt

FSP1

24

gctcaacaagtcagaactaaaggag

gcagcttcatctgtccttttc

78 nt

GAPDH

60

agccacatcgctcagacac

gcccaatacgaccaaatcc

66 nt
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Protein Extraction and Western Blot Analysis: Protein is extracted by lysis of cell pellets with
RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5 % sodium deoxycholate, 1 % Triton X 100 and
protease inhibitor cocktail) and protein concentrations are determined by performing a BSA
assay as per the manufacturers’ instructions (Pierce). 25 ug protein of each sample is then run
on an SDS-PAGE gel and transferred to a PVDF membrane using the Bio-Rad western blotting
system. Membranes are probed with Cav-1 (Cell Signaling Technology, 1:2500 dilution) and
GAPDH (Santa Cruz Technology, 1:1000 dilution) antibodies.

CAV1 3’UTR Identification and Cloning: Bioinformatic tools are available on the web that predict
the potential candidate mRNA targets of any given miRNA. However, these putative targets
must be validated through experimental approaches. We consulted the miRNA target prediction
websites, TargetScan (http://targetscan.org) and Miranda (http://www.microrna.org), linked on
miRBase (http://mirbase.org) for miR-510 to score for putative targets of miR-510. Both
TargetScan and Miranda microRNA target prediction databases list CAV1 as a potential direct
target of miR-510. CAV1 3’UTR luciferase reporter vector purchased from Genecopoeia.

Site directed mutagenesis (SDM): The miR-510 seed site within the 3’UTR of CAV1 is mutated
using the site directed mutagenesis kit from Stratagene as per the manufacturer’s instructions.
Potential clones are sequenced to verify the correct mutation.

Dual Luciferase Assay: The CAV1 3’UTR luciferase reporter clone along with an empty vector
(EV) control are transiently transfected into HEK-293 cells with and without miR-510 expression,
and then 48 hours later the luciferase activity is measured. In addition, we will mutate the seed
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sequence of miR-510 in the Cav-1 3’UTR by site-directed mutagenesis (Stratagene) and confirm
that the predicted miR-510 binding site is the actual binding site for miR-510.

Co-culture experiments: MDA-MB-231 tumor epithelial cells are cultured in a non-contact
manner with WPMY1 stromal fibroblasts using a transwell migration system [Figure 8]. WPMY1
stromal fibroblasts are plated in the bottom of a 6-well dish at a density of 2.0x105 cells/2mL in
complete media and breast epithelial cells, either expressing miR-510 or a scrambled control,
are seeded at a density of 2.0x105 cells/1mL into the upper chamber of a Transwell insert with a
pore size of 0.4 µM. The MDA-MB-231 tumor epithelial cells in the upper chamber are unable to
move through the pores, however microvesicles derived from the MDA-MB-231 tumor epithelial
cells are able to move through the pores and into the lower chamber where they can
interact/fuse with the WPMY1 stromal fibroblasts. After 48h, the fibroblasts in the lower
chamber are collected for RNA and protein analysis. A transwell insert containing media only
serves as an additional negative control.

Figure 8: Schematic
representation of co-culture
model
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Conditioned media experiment: WPMY1 stromal fibroblasts plated in a 6-well dish at a density of
2.0x105 cells are incubated with 2mL/well of conditioned media from MDA-MB-231 tumor
epithelial cells for 24h to assess whether miR-510 is present in the media from MDA-MB-231
tumor epithelial cells in the absence of any neighboring cell stimulation and RNA and protein
analysis performed as described above.

Migration Assay: MDA-MB-231 tumor epithelial cells are cultured in a non-contact manner with
WPMY1 stromal fibroblasts using a transwell migration system [Figure 8]. WPMY1 stromal
fibroblasts are plated in the bottom of a 6-well dish at a density of 2.0x105 cells/2mL in complete
media and breast epithelial cells, either expressing miR-510 or a scrambled control, are seeded
at a density of 2.0x105 cells/1mL into the upper chamber of a Transwell insert with a pore size of
0.4 µM. After 48h, the fibroblasts in the lower chamber are collected and counted. The
fibroblasts collected from the lower chamber are then seeded at a density of 5.0x104
cells/500µL in serum free media into the upper chamber of a new Transwell insert with a pore
size of 0.8 µM. 500µL of complete media is added to wells in a 24-well dish. Inserts are placed
into each well and incubated at 37°C for 4h. After 4h, the inserts are cleaned and placed in new
wells with 500 µL of 3.7% formaldehyde for 15 minutes, followed by two washes with PBS for 3
minutes each. Inserts are then placed in new wells with 2% crystal violet for 30 minutes. Inserts
are washed in Millipore water and air dried. Migrated cells are quantified by averaging the count
of migrated cells in 5 planes.

Exosome isolation: MDA-MB-231 tumor epithelial cells are cultured in a non-contact manner
with WPMY1 stromal fibroblasts using a transwell migration system [Figure 8]. WPMY1 stromal
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fibroblasts are plated in the bottom of a 6-well dish (notched for use with cell culture inserts to
collect ample media for exosome isolation) at a density of 5.0x105 cells/2mL in complete media
with exosome-depleted FBS. Breast epithelial cells, either expressing miR-510 or a scrambled
control in serum-free media, are seeded at a density of 5.0x105 cells/1mL into the upper
chamber of a Transwell insert with a pore size of 0.4 µM. The MDA-MB-231 tumor epithelial
cells in the upper chamber are unable to move through the pores, however microvesicles
derived from the MDA-MB-231 tumor epithelial cells are able to move through the pores and
into the lower chamber where they can interact/fuse with the WPMY1 stromal fibroblasts. After
48h, the fibroblasts in the lower chamber are collected for exosome isolation, using the
exosome isolation kit from PureExo. Following collection of 2mL of cell culture medium, the cell
media is centrifuged at 2,000 RPM for 10 minutes at 4ºC to remove cells or debris. The cell-free
culture media is then transferred to a new glass tube and prepared mixture A/B/C from the kit is
added, followed by a vigorous 30 second vortex and 30 minute incubation at 4ºC. Following
incubation, the top of 2 layers is aspirated and discarded without disturbing the bottom fluff
layer. The fluff layer is transferred to a new micro centrifuge tube and spun at 5,000 RPM for 3
minutes. A new 3-layer separation occurs, the top and bottom layers are removed, and the
remaining middle fluff layer is transferred to a new micro centrifuge tube. After centrifugation
at 5,000 RPM for 3 minutes, the tube cap is left open to air dry for 5-10 minutes at RT. 200µL of
PBS is added to resuspend the collected fluff. The tube is left on a horizontal shaker for 10
minutes, followed by pipetting up and down vigorously. The tube is spun at 5,000 RPM for 5
minutes and the supernatant carefully transferred into provided PureExo Column. The column is
spun at 1,000 RPM for 5 minutes to collect all flow-through. The flow-through is the isolated
exosome suspended in PBS. MicroRNA is then extracted from exosomes using the microRNA
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extraction kit from Qiagen as per the manufacturer’s instructions. qPCR, Reverse Transcription,
and downstream analysis are performed as described as above.

Statistical Analysis: For statistical testing, two-sided paired Student's t-tests were done using
Excel spreadsheet. p values are given for each individual experiment, but in general, p< 0.05 was
considered statistically significant. Error bars represent standard deviations of three
independent experiments unless indicated otherwise.
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Specific Aim 1 Results:
Cav-1 is a direct target of miR-510.
In order to determine if CAV1 is a direct target of miR-510, HEK-293 cells were transiently
transfected with a luciferase reporter vector containing the wild type CAV1 3’UTR (CAV1 UTR) or
mutant CAV1 3’UTR with deletion of the bioinformatically predicted miR-510 seed site (CAV1
SDM) and either miR-510 or a scrambled control (scr). Dual luciferase assays were performed
48h after transfection and we observed a 66% reduction in luciferase activity in the cells
transfected with both the CAV1 3’UTR and miR-510 when compared to the scr control [Figure
9A]. In the cells transfected with the mutant CAV1 construct, a much lower reduction (~20%) in
luciferase activity was observed in the cells co-transfected with miR-510 when compared to the
scr control. qPCR for miR-510 serves as a control and shows a successful transfection of miR-510
into HEK-293 cells [Figure 9B]. These data suggest that miR-510 directly binds to 3’UTR of CAV1
and that this occurs through the predicted seed site, shown in Figure 9C.
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Figure 9: Dual luciferase assay. HEK-293 cells transfected with
luciferase construct containing Cav-1 3’UTR mutated at miR-510
seed sequence (A). qPCR quantitation of miR-510 expression in
cultured HEK-293 cells (B). Predicted seed site for miR-510 on
3’UTR of CAV1 (C).
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miR-510 expression modulates Cav-1 expression specifically in stromal cells.
To assess whether miR-510 negatively regulates protein expression in vitro, western blot
analysis was performed on epithelial cell lines and stromal cell lines following transfection of
miR-510. MDA-MB-231 and MCF10a epithelial cells overexpressing miR-510 do not show a
reduction in Cav-1 protein expression levels [Figure 10A; Figure 10B], suggesting that it does not
negatively regulate Cav-1 in these cells. However, Cav-1 expression in breast tumor epithelial
cells is not associated with poor survival in breast cancer patients, suggesting the mechanism of
miR-510 regulation of Cav-1 in breast epithelial cells does not contribute to poorer prognosis.
WPMY1 and 3T3 stromal fibroblasts transfected with miR-510 show a reduction in Cav-1 protein
expression levels [Figure 10C; Figure 10D], providing encouraging evidence that upregulation of
miR-510 may be the mechanism of Cav-1 loss in stromal cells. qPCR for Cav-1 mRNA in all cell
types shows no significant change in Cav-1 mRNA expression [Figure 10].
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Figure 10: miR-510 expression modulates Cav-1 expression in stromal cells,
but not in epithelial cells. Western blot analysis for Cav-1 protein in
epithelial cells transfected with miR-510 shows no reduction in Cav-1
protein expression. qPCR quantitation for Cav-1 mRNA shows no significant
change in Cav-1 mRNA expression (A,B). Western blot analysis for Cav-1
protein in stromal cells transfected with miR-510 shows a reduction in Cav-1
protein expression. qPCR quantitation for Cav-1 mRNA shows no significant
change in Cav-1 mRNA expression (C,D).
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miR-510 levels are elevated in fibroblasts co-cultured with, or treated with conditioned media
from, miR-510 expressing epithelial cells. To determine whether miR-510 expressed in
epithelial cells is transferred to fibroblasts we performed co-culture experiments with MDA-MB231 breast tumor epithelial cells either stably expressing miR-510 or scr control in the upper
well of a transwell insert and WPMY1 normal fibroblasts in the bottom [Figure 11A]. Transwell
inserts with no cells (just media) in the upper chamber were included as an additional negative
control. 24 hours after cells were cultured together, WPMY1 fibroblasts were collected and we
performed qPCR for miR-510 expression. We observed a significant increase in the levels of miR510 in the WPMY1 fibroblasts co-cultured with miR-510 expressing MDA-MB-231 epithelial cells
when compared to both the scr and media alone controls [Figure 11B]. We observed no
difference between WPMY1 fibroblasts co-cultured with scr control MDA-MB-231 epithelial cells
and media alone. To assess whether miR-510 is present in the media from MDA-MB-231 tumor
epithelial cells in the absence of any neighboring cell stimulation, conditioned media from miR510 expressing MDA-MB-231 epithelial cells was applied to WPMY1 fibroblasts for 24h. WPMY1
fibroblasts were collected and we performed qPCR for miR-510 expression. We observed a
significant increase in the levels of miR-510 in the WPMY1 fibroblasts treated with conditioned
media from miR-510 expressing epithelial cells [Figure 11C].
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Figure 11: miR-510 levels are elevated in fibroblasts cocultured with, or treated with conditioned media from, miR510 expressing epithelial cells. Schematic representation of coculture experiment (A). qPCR of miR-510 expression in cocultured WPMY1 fibroblasts (B). qPCR of miR-510 expression in
WPMY1 fibroblasts treated with conditioned media from miR510 expressing epithelial cells (C).
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Cav-1 protein is reduced in fibroblasts co-cultured with, or treated with conditioned media
from, miR-510 epithelial cells. To determine whether Cav-1 protein expression is modulated in
fibroblasts by epithelial derived miR-510, we performed western blot analysis on WPMY1
fibroblasts co-cultured with miR-510 expressing MDA-MB-231 cells as described above. We
observed a reduction in Cav-1 protein in fibroblasts co-cultured with miR-510 epithelial cells
[Figure 12A]. To determine whether the presence of stromal cells is required to signal the
epithelial cells to secrete miR-510, we performed western blot analysis on WPMY1 fibroblasts
treated with conditioned media from MDA-MB-231 epithelial cells [Figure 12B]. We observed a
decrease in Cav-1 protein levels in cells treated with conditioned media from miR-510
expressing breast tumor epithelial cells when compared to the scr control suggesting that the
cells do not need to be cultured together for epithelial cells to secrete miR-510.

Figure 12: Cav-1 protein is reduced in fibroblasts co-cultured with
miR-510 epithelial cells and in fibroblasts treated with conditioned
media from miR-510 expressing epithelial cells. Western blot
analysis for Cav-1 in WPMY1 stromal fibroblasts co-cultured with
miR-510 overexpressing MDA-MB-231 tumor epithelial cells shows
decrease in Cav-1 protein expression (A). Western blot analysis for
Cav-1 in WPMY1 stromal fibroblasts treated with conditioned
media from miR-510 overexpressing MDA-MB-231 tumor
epithelial cells shows decrease in Cav-1 protein expression (B).
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Fibroblasts co-cultured with miR-510 expressing epithelial cells are activated to a CAF
phenotype. To determine whether fibroblasts co-cultured with miR-510 overexpressing breast
tumor epithelial cells are ‘activated’, we performed co-culture experiments as described above,
followed by qPCR for COL1A1 (collagen) and FSP1 (fibroblast specific protein), genes that are
used as CAF markers [56]. We observed a significant increase in the levels of both collagen and
FSP1 (~12 fold) in the WPMY1 fibroblasts that were co-cultured with miR-510 expressing MDAMB-231 epithelial cells when compared to the scr control [Figure 13].

Figure 13: Stromal fibroblasts are activated to a CAF
phenotype when co-cultured with mir-510 overexpressing
epithelial cells. qPCR quantitation for CAF markers collagen
and FSP1 shows increase in WPMY1 fibroblasts co-cultured
with MDA-MB-231 epithelial cells overexpressing miR-510.
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Fibroblasts co-cultured with miR-510 expressing epithelial cells show increased migration.
To determine if the ‘activated’ WPMY1 stromal fibroblasts are more aggressive compared to the
non-activated scr controls, we performed a migration assay on WPMY1 fibroblasts that had
been co-cultured with miR-510 expressing MDA-MB-231 breast tumor epithelial cells or scr
controls for 24 hours [Figure 14]. We observed a 60% increase in the migratory capacity of the
‘activated’ fibroblasts indicating that these stromal fibroblasts are more aggressive.

Figure 14: Migration assay.
WPMY1 stromal fibroblasts cocultured with MDA-MB-231 tumor
epithelial cells show 60% increase
in migration.
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miR-510 is not transferred from tumor epithelial cells to nearby stromal cells via exosomes.
To determine if epithelial derived miR-510 is transferred to neighboring fibroblasts via
exosomes, we isolated exosomes from the co-culture studies as described above and performed
qPCR for miR-510. We expected to see high expression of miR-510 in the isolated exosomes,
providing evidence that miR-510 is being transferred via exosomes. However, qPCR for miR-510
revealed that no miR-510 was detectable in our isolated exosomes. To verify that we had
isolated intact exosomes, we performed qPCR for miR-21 as this is a miRNA that has been
shown to be present in exosomes isolated from MDA-MB-231 conditioned media [57]. We were
able to show that miR-21 was present in exosomes isolated from WPMY1 fibroblasts co-cultured
with either miR-510 expressing breast tumor epithelial cells and scr controls [Figure 15].

Figure 15: miR-510 is not
detectable in isolated exosomes
from co-culture study. qPCR for
miR-510 and miR-21 in isolated
exosomes.
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Specific Aim 2: To test the hypothesis that elevated miR-510 expression in breast epithelium
promotes tumorigenesis through the negative regulation of Cav-1 expression in the stroma

Rationale: Cav-1 behaves as a transformation suppressor in fibroblasts [44]; therefore,
downregulation of Cav-1 is a mechanism implicated in the oncogenic transformation of
fibroblasts to CAFs [38; 43]. A study conducted by Sotgia and colleagues provided the first
molecular genetic evidence that loss of Cav-1 expression directly contributes to the CAF
phenotype [44]. Sotgia and colleagues prepared mammary stromal fibroblasts (MSFs) from wildtype and Cav-1−/− mice and then subjected them to genome-wide transcriptional profiling.
Interestingly, the Cav-1−/− mammary stromal fibroblast transcriptome significantly overlapped
with that of human breast CAFs, as they identified a list of 55 genes that were commonly upregulated in both human breast CAFs and Cav-1−/− mammary stromal fibroblasts [Figure
16]. Both show a nearly identical profile of RB/E2F (retinoblastoma/ E2 promotor binding
factor)-regulated genes that are up-regulated, which is consistent with RB inactivation [24; 44].
When RB is hypo-phosphorylated in quiescent or differentiated cells, it interacts with the E2F
family to repress the transcription of genes necessary for cell cycle progression [24]. When
researchers examined the state of phosphorylation in human breast CAFs and Cav-1−/− MSFs, RB
was hyper-phosphorylated compared to normal fibroblasts, resulting in RB inactivation [24; 44].
This study concluded loss of Cav-1 expression may be a critical initiating event leading toward
the CAF phenotype, as the replacement of Cav-1 expression in CAFs is sufficient to revert their
hyper-proliferative phenotype and prevent RB hyper-phosphorylation [24; 44]. Therefore, this
aim will explore if elevated expression of miR-510 in vivo results in a reduction of Cav-1 and
determine its effects on tumor derived fibroblasts and tumorigenesis.
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Figure 16: CAF versus Cav-1−/− mammary stromal
fibroblast (MSF) gene signatures. Venn diagrams
summarizing the similarities and differences between
gene transcript changes in human breast CAFs and Cav1−/− mammary stromal fibroblasts. Adapted from Sotgia
F, et al 2009.
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Preliminary Data
miR-510 promotes tumor growth in vivo. To assess the functional effects of miR-510 in vivo,
nude mice were injected orthotopically with MDA-MB-231 cells stably infected with miR-510 or
scr control. Tumor growth was monitored twice weekly for approximately 30 days. Tumors from
both miR-510 expressing and scr controls appeared to initiate at a similar time frame. Published
data from our lab shows that by three weeks the miR-510 expressing tumors were growing
more rapidly, and by the end of the study, the miR-510 expressing tumors were larger than the
scr controls [52; Figure 17]. Following this previous study, our current study asked the question,
“Do miR-510 overexpressing tumors result in more aggressive fibroblasts in the tumor
microenvironment than scr control tumors?”

Figure 17: miR-510 promotes tumor growth in vivo.
Average tumor volumes of mice orthotopically
injected with MDA-MB-231 cells stabling infected with
miR-510 or scr control show that cancer cells
overexpressing miR-510 result in faster tumor growth
compared to scr control tumors. Adapted from Guo Q,
et al 2013.
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Specific Aim 2 Tasks:
Task 1: Orthotopically inject 6 week old nude mice with MDA-MB 231/scr and MDA-MB 231/510
cells and allow to grow to maximum size (~1500mm3)
Task 2: Harvest tumors and isolate CAFs
Task 3: Assess enriched population of CAFs by qPCR to identify:


CAF associated markers: COL1A1 and FSP1

Task 4: IF staining of isolated CAFs to determine:


If miR-510 expressing CAFs show a reduction of Cav-1 protein

Task 4: Orthotopically co-inject scr or miR-510 CAFs and MDA-MB-231 cells into nude mice and
monitor tumor growth/size over time to assess:


If miR-510 derived CAFs results in more aggressive tumor growth

Task 5: IHC of Cav-1 in scr CAF:231, 510 CAF:231, MDA-MB-231 alone tumors to determine:


If expression of miR-510 results in a reduction of Cav-1 in vivo
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Methods
Xenograft Assay (in vivo): MDA-MB-231 cells either expressing miR-510 or scrambled control are
orthotopically injected into 6 week old nude mice and allowed to grow until the tumors reach a
size of ~1.5 cm. Tumors (two per mouse from 68 mice) are harvested from euthanized mice
immediately following isoflurane asphyxiation according to IACUC protocols. CAFs are isolated
as described below. Following CAF isolation, 5 x 104 MDA-MB-231 cells are co-injected
orthotopically into 6 week old nude mice, with 1.5 x 105 CAFs isolated from either miR-510
expressing or scrambled control tumors, and tumor size/volume is monitored bi-weekly by
calipers. Orthotopic injections into 32 total mice of 2 x 105 MDA-MB-231 cells, miR-510 or
scrambled CAFs alone serve as additional controls. Animals are euthanized at day 64 and solid
tumors, lungs and other organs (kidney, liver) are excised to assess for macro metastasis.

CAF Isolation: Tumors are cut into small 1-2 mm pieces followed by digestion in a 0.5mg/ml
Collagenase I (Sigma) solution of aMEM for 35 minutes at 37°C in a shaking incubator. The
digested tumor suspension is vortexed on high for 30 seconds before filtration through a 40µM
cell strainer. The filtered solution is centrifuged at 1600 rpm for 5 minutes and the pellet
resuspended in 5ml 0.1% BSA/PBS. The resuspended pellet is centrifuged at 1600rpm for 5
minutes and the resultant pellet resuspended in 20% FBS/aMEM + Pen/Strep (P/S) and plated.
48 hours after plating the cells are trypsinized with 1 ml of 0.25% trypsin-EDTA for
approximately 3 minutes with rocking to remove tumor cells. To stop the action of the trypsin, 5
ml of CAF media (20% FBS/aMEM + P/S) is added and then immediately removed. The plate is
washed twice with either CAF media or HBSS (no AA). Finally, 10 ml of CAF media is added to the
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plate and returned to the incubator to recover for 24 hours before using the cells. The expected
yield is approximately 150,000 CAFs/tumor.

Immunofluorescence Assay: 200 µL of fibronectin is placed on a coverslip in a 12-well plate 2
hours prior to plating cells. 5 x 104 CAFs in 0.5mL CAF media are plated. Growth media is
removed by aspiration and washed twice in 1 x PBS. Cells are fixed in 1 mL of 3.7%
formaldehyde in 1 x PBS pH7 and incubated at room temperature (RT) for 15 minutes, followed
by 3 washes with cold 1 x PBS. Cells are permeabilized with 1 mL of 0.1% Triton X-100 in 1 x PBS
for 20 minutes, followed by 2 washes with cold 1 x PBS. 2 mL of 2% BSA in 1 x PBST is added for
24 hours to reduce background signal. A 1:100 dilution of primary antibody Cav-1 (560
fluorescent wavelength) in 2% BSA in PBST is applied and incubated for 2 hours at RT. Excess
antibody is washed 3 times with 1 x PBST for 10 minutes with gentle agitation. To reduce
background signal from secondary antibody, 2 mL of 1% BSA in 1 x PBST is added for 2 hours. A
1:100 dilution of secondary antibody, α-rabbit, in 1% BSA in 1 x PBST is applied, followed by
incubation at RT for 30-40 minutes. Cells are washed 2 times with 1 x PBS (5 minutes each). 1 µL
of HOECHST (1:10000 dilution) is added, and cells incubated for 8 minutes at RT. Excess antibody
is washed 3 times with 1 x PBST for 5 minutes with gentle agitation. Slides are mounted with
Prolong Gold-Antifade reagent. 5 images per sample are taken on a Nikon A1r confocal
microscope with 1 representative image selected.

Tissue sectioning: MDA-MB-231 scr and miR-510 tumors from the in vivo study are stored in 70%
ethanol at 4°C. The tumors are dehydrated by passing through 95% ethanol twice and then
100% ethanol twice, for 1 hour each. Tumor samples are then placed into 100% toluene twice
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for 4 hours each. Next the tumors are placed in a 50:50 mixture of toluene/paraffin overnight at
60°C. The 50:50 mixture of toluene/paraffin is removed and 100% paraffin is added to the
samples, twice for 2 hours each, at 60°C. The samples are embedded in cassettes with the
EG1160 paraffin embedding station (Leica, Buffalo Grove, IL). The tumors are then sectioned (5
microns thickness) with Jung RM2055 microtome (Leica, Buffalo Grove, IL) and mounted onto
Superfrost Plus glass slides (Fisher, Hampton, NH) for immunohistochemistry (IHC).

Immunohistochemistry (IHC): Tumors from the in vivo experiment are fixed and embedded in
paraffin blocks. The tumors are then sectioned (5 microns) and mounted onto glass slides for
immunohistochemistry (IHC). For IHC, slides are incubated in a 60°C oven for 1 hour and then
placed in xylene (Fisher, Hampton, NH) for 10 minutes and then rehydrated with serial
incubations in decreasing ethanol concentrations (100%, 95%, 70% and 50%) for 10 minutes
each. Next, the slides are subjected to heat-induced antigen retrieval by heating slides in a
vegetable steamer with 1% citrate buffer solution (Vector Labs, Burlingame, CA) for 30 minutes.
Slides are further washed with 1X PBS twice for 3 minutes each and then incubated with 0.3%
hydrogen peroxide (Fisher, Hampton, NH) to sequester endogenous peroxidase activity for 30
minutes. Next, the slides are washed with 1x PBS-Tween (0.05%) for 5 minutes before blocking
with 2.5% horse serum (Vector Labs, Burlingame, CA) at 25°C in an incubation chamber. A 1:250
dilution of primary antibody, Cav-1, is then applied and incubated overnight at 4®C. Slides are
washed 3 times with 1 x Phosphate Buffer Solution (PBS), and then incubated with a dilution of
1:200 secondary antibody (Vector Labs, α-rabbit) at RT for 30 minutes. The slides are then
incubated with Diaminobenzidine (DAB) for 1 minute and then counterstained with
hematoxylin. Slides are then dehydrated with serial incubation in increasing concentrations of
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ethanol (50%, 70%, 95% and 100%) and xylene for 5 minutes each. Finally, slides are mounted
with Permount (Fisher, Hampton, NH) and a glass coverslip (Fisher, Hampton, NH). 5 images per
tumor are taken on a Nikon 90i light microscope at 20x magnification with 1 representative
image selected. For Cav-1 quantitation, images are scored based on intensity of staining from 1
representative image each (0 for no staining, 1 for low staining, 2 for moderate staining, 3 for
high staining, and 4 for very high staining). These scores are plotted.
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Results
Fibroblasts were isolated from miR-510 expressing and scr control breast tumors. In order to
isolate an enriched fibroblast population, mice were injected with MDA-MB-231 cells
overexpressing miR-510 or MDA-MB-231 cells expressing a scr control, and tumor growth was
monitored as they grew to maximum size (1500mm3) [Figure 18]. Following isolation of
fibroblasts from those miR-510 and scr expressing tumors, we performed qPCR for fibroblast
marker FSP1 and epithelial cell marker ESA [Figure 19A]. qPCR shows that the extracted
fibroblasts express fibroblast marker FSP1 and show little to no expression of epithelial cell
marker ESA. We also performed qPCR for miR-510 in isolated fibroblasts [Figure 19B]. The
isolated fibroblasts express miR-510, providing evidence for an indirect transfer of miR-510 from
tumor epithelial cells due to the lack of genomic mouse miR-510.

Figure 18: Schematic
representation of mouse injections
for enriched fibroblast isolation
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Figure 19: Fibroblasts were isolated from miR-510 expressing
and scr control tumors. qPCR for fibroblast marker FSP1 shows
elevated FSP1 in miR-510 expressing CAFs and little expression
of epithelial marker ESA (A). qPCR for miR-510 shows
extracted fibroblasts from miR-510 expressing tumors express
miR-510 (B).
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Cav-1 is reduced in miR-510 expressing CAFs.
To determine if miR-510 expressing CAFs show a decrease in Cav-1 expression, we performed IF
staining on our enriched CAF population. Total number of cells, including epithelial cells and
CAFs, were counted in 5 fields for scr CAFs and 510 CAFs. Table 2 shows percentage of CAFs in
total cell population, as well as percentage of CAFs with Cav-1 positive staining. Representative
images of staining intensity reveal CAFs isolated from miR-510 expressing breast tumors show a
reduction in Cav-1 protein expression compared to CAFs from scr control tumors [Figure 20].

Table 2: Quantitation of IF CAFs

scr CAFs
510 CAFs

CAFs/ Total Cell
population

Cav-1 positive
staining

p value

53%
43%

88%
47%

p<.04
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Figure 20: Representative images of Cav-1 staining intensity of
CAFs. Cav-1 protein is reduced in CAFs derived from miR-510
expressing tumors compared to CAFs derived from scr control
tumors. Images are 20x magnification.
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Fibroblasts extracted from miR-510 expressing tumors are activated to a CAF phenotype.
Following isolation of fibroblasts from miR-510 and scr expressing tumors as described above,
we performed qPCR for activated fibroblast marker COL1A1 (collagen) [Figure 21]. Extracted
fibroblasts from miR-510 expressing tumors are activated to a CAF phenotype, as shown by
increased expression of activated fibroblast marker COL1A1 (collagen). This data is also
supported by qPCR for fibroblast marker FSP1 and epithelial cell marker ESA, showing that the
extracted fibroblasts express fibroblast marker FSP1 and show little to no expression of
epithelial cell marker ESA [Figure 19A].

Figure 21: Isolated fibroblasts from miR-510
expressing tumors are activated to a CAF
phenotype. qPCR shows increased expression of
collagen (activated fibroblast marker).
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miR-510 expressing CAFs result in more aggressive tumor growth.
In order to determine whether miR-510 expression results in a more aggressive CAF, 6 week old
nude mice were orthotopically injected with: (1) CAFs isolated from scr control tumors + MDAMB-231 cells (scr CAF:231); (2) CAFs isolated from miR-510 expressing tumors + MDA-MB-231
cells (510 CAF: 231); and (3) MDA-MB-231 epithelial cells alone (231) [Figure 22]. CAFs derived
from miR-510 and scr control tumors were also injected alone to serve as additional controls.
Tumor volume was monitored twice weekly throughout the study for 64 days. Comparing the
tumors resulting from the 231 only controls with the 510 CAF:231 tumors, the 510 CAF:231
tumors grew faster and were much larger at the end of the study [Figure 23A]. Tumor weight
showed the same trend as tumor volume [Figure 23B]. The scr CAF:231 tumors did not lead to a
more aggressive tumor growth when compared to the 231 tumors alone suggesting that the scr
CAFs were not aggressive enough to drive tumor growth. These results suggest that miR-510
expression in breast tumor epithelial cells leads to a more aggressive CAF in the tumor
microenvironment and more aggressive tumor growth.
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Figure 22: Schematic
representation of CAF coinjections
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Figure 23: MDA-MB-231 tumor growth and weight. Average tumor
volumes of mice orthotopically injected with MDA-MB-231 cells
alone or co-injected with miR-510 expressing CAFs or scr control
CAFs. Normalized to CAF only injections (A). Average tumor masses
of experimental groups at the conclusion of the study (B).
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Cav-1 is reduced in 510 CAF:231 tumors.
In order to assess the levels of Cav-1 in vivo we performed IHC staining of tumors extracted from
the mice described above. Cav-1 IHC of the tumor sections shows an overall reduction of Cav-1
expression in 510 CAF:231 tumors compared to scr CAF:231 and 231 tumors [Figure 24]. Stromal
vs. epithelial staining is not specified. Quantitation of tumor Cav-1 protein expression with
representative tumors from each experimental group is shown [Figure 25]. Tumors were
grouped together based on Cav-1 IHC score and plotted. This data suggests that miR-510
modulates Cav-1 expression in vivo.
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Figure 24: IHC of tumors from in vivo study. Representative
images of hematoxylin & eosin and Cav-1 staining in MDAMB-231 only, scr CAF:231, and 510 CAF:231 tumors. 20x
magnification.
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Figure 25: Cav-1 expression in
tumors from in vivo study.
Quantitation of Cav-1 IHC in
tumors from in vivo study with
tumors grouped based on Cav-1
IHC score. Representative images
of Cav-1 IHC Scores are shown at
20x magnification.
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Discussion
In our state of South Carolina, mortality differences between AA and CA breast cancer patients
are amongst the highest in the country. Growing evidence shows that racial disparity in breast
cancer exists due to molecular differences in tumor biology in addition to socioeconomic and
standard of care issues [6; 9; 10]. A greater understanding of the genetic and biological
differences associated with breast cancer will significantly impact AA communities due to the
higher deaths associated with the disease in this population. Sparse information exists regarding
the molecular mechanisms that promote this breast cancer health disparity. Our studies have
identified a potential race specific mechanistic link between miR-510 and Cav-1 [Figure 1].
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Figure 1: Conceptual Model. Breast cancer disparities are attributed to
a combination of sociodemographic factors and inherent biological
factors. Disparities also exist independently of sociodemographic
factors. Aim 1 of this project examines a biological mechanism
contributing to breast cancer disparities, while Aim 2 examines
functional outcome of this mechanism.
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Results showing negative Cav-1 regulation by miR-510 in fibroblasts is promising, suggesting that
miR-510 is a mechanism of stromal Cav-1 loss in breast cancer. Interestingly, miR-510
overexpression in MDA-MB-231 and MCF10a epithelial cells does not have an effect on Cav-1
protein expression. However, there is no known association between Cav-1 expression in the
epithelial compartment and clinical outcome [34; 36; 37; 40], which reinforces the idea that
stromal Cav-1 expression is a primary determinant of clinical outcome in breast cancer patients.
These in vitro experiments [Figure 10] could be strengthened by repeating them in AA and CA
cell lines. We would expect to see a greater reduction of Cav-1 protein in AA cell lines compared
to CA, providing more relevance to the disparity component of this project. Cav-1 expression
may also be disparate between races, as data mining on Oncomine revealed that Cav-1 mRNA
levels are lower in AA with breast cancer (tumor epithelial or stromal not specified) when
compared to CA women. In addition, miR-510 expression in breast cancer patients is disparate
between races, as we observed an elevation in miR-510 levels in serum samples extracted from
AA breast cancer patients when compared to their benign counterparts. This difference was not
observed in CA breast cancer patients. Limitations to the miR-510 serum data include a small
sample size. However, these findings suggest loss of stromal Cav-1 mediated by miR-510 may be
the mechanism leading to poorer breast cancer survival in AA women and warrants further
investigation of its role in promoting breast cancer disparity. We are active collaborators with
Dr. Ashley Evans-Knowell at South Carolina State University, and her group is investigating the
correlation between miR-510 and Cav-1 expression in tissue from AA and CA breast cancer
patients. These data will allow us to determine whether a true negative correlation exists in
breast cancer patients and specifically in AA patients.
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We hypothesized that tumor derived microvesicles deliver miR-510 from epithelial cells to
recipient fibroblasts in the tumor microenvironment, resulting in a loss of stromal Cav-1 protein
expression, and that this may provide a biological mechanism promoting breast cancer disparity
[Figure 1]. To address this, we performed qPCR for miR-510 in CAFs isolated from miR-510
expressing tumors. This upregulation of miR-510 in the isolated mouse-derived CAFS provides
evidence of an indirect transfer of miR-510 from human epithelial cells to resident fibroblasts as
mice do not have miR-510 encoded in their genome. Tumor derived microvesicles can also result
in circulating miRNAs in the blood and can serve as accessible biomarkers for diagnosis and
prognosis [47; 49]. In addition, they may define a novel area of potential therapeutic
intervention to reduce cancer disparity. This study shows that co-culture of miR-510 expressing
tumor epithelial cells with fibroblasts in vitro leads to downregulation of Cav-1 in the fibroblasts.
We have also shown that conditioned media from miR-510 expressing tumor epithelial cells
leads to Cav-1 downregulation in stromal fibroblasts, demonstrating that cell-to-cell contact is
not required for miR-510 transfer. We examined miR-510 levels in exosomes isolated from the
media of co-culture studies to determine if exosomes were the transport vesicle for miR-510.
However, miR-510 was not detectable in isolated exosomes, demonstrating this this in not their
method of transfer. However, qPCR for miR-21 was positive, demonstrating that our exosome
isolation was successful. In the future, those exosomes could be further verified by electron
microscopy or characterized by exosome protein markers using Western blot analysis.

Although exosomes are the most widely studied of extracellular vesicles, studies show that
malignant tumor cells release a heterogeneous population of microvesicles [54]. Therefore; it is
necessary to further study alternative tumor-derived microvesicles in which miR-510 could be
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transferred. Exosomes and microvesicles are terms often used interchangeably, as they are both
membrane-bound vesicles capable of miRNA transfer. But they can be characterized according
to different properties, including biogenesis and physical properties. Exosomes are a
homogenous population with a size of 40-100nm in diameter and are derived from the
endocytic recycling pathway, while microvesicles are a heterogeneous population with a size of
50-1000nm in diameter and are produced directly from outward budding and fission of the
plasma membrane [55]. Moving forward, our lab could perform a microvesicle preparation
utilizing stromal fibroblasts from our co-culture model, followed by characterization and
identification of those microvesicles, and then probe for miR-510 by qPCR.

Our alternative hypothesis is that a release of cytokines or growth factors from epithelial tumor
cells leads to an upregulation of miR-510 in neighboring stromal cells. Studies have reported
that tumor-derived microvesicles showed the presence of chemokine (a subpopulation of
cytokines) receptors CCR6 and CD44v7/8, signaling factors TGFβ1/2, and contained mRNA for
growth factors including VEGF and interleukin-8 (IL-8) [56; 57]. Interestingly, TGFβ1/2 and VEGF
released from tumor cells is implicated in the oncogenic transformation of fibroblasts to CAFs
[56]. Following exhaustion of probing for miR-510 in microvesicles from our co-culture studies,
these signaling pathways could be studied for their contribution to breast cancer disparities.

Results from our in vivo studies was supportive of our hypothesis. We were able to successfully
isolate a cell population enriched for CAFs. We used qPCR to first validate that our extracted
fibroblasts expressed fibroblast markers, then to show a transfer of miR-510 from miR-510
expressing tumors to the CAFs, and finally to verify that our extracted fibroblasts had been
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activated to a CAF phenotype. IF for enhanced CAFs also showed a decrease in Cav-1 expression,
supporting our hypothesis that miR-510 negatively regulates Cav-1. Future studies will co-stain
with antibodies against αSMA and wide spread cytokeratin to identify activated fibroblasts
versus epithelial cells.

Tumors from miR-510 CAF:231 co-injections resulted in faster tumor growth and larger tumors
at the end of the study than tumors derived from injection of MDA-MB-231 cells alone.
Interestingly, we observed macro metastasis in the liver of one of the experimental mice that
correlated with the largest tumor size. Unexpectedly, we observed tumor growth in some of our
control CAF only injections. Therefore, we normalized our experimental co-injection groups to
CAF only injections in order to accurately reflect tumor growth. We suspect that our CAF only
tumors grew due to poor experimental design, as CAF only controls were injected on the same
mice as experimental co-injections. It is possible that the enriched CAF populations had a small
percentage of contaminating epithelial cells and that paracrine factors released by malignant
tumors caused these cells to grow. The scr CAF:231 co-injection tumors did not grow as well as
the MDA-MB-231 tumors alone, suggesting that the scr CAFs were not aggressive enough to
drive tumor growth.

IHC revealed an expected overall decrease of Cav-1 expression in 510 CAF:231 tumors at 20X
magnification. Future studies will stain with antibodies against epithelial and stromal cells in
order to determine Cav-1 loss in specific tumor compartments. Future studies will also examine
potential increases in angiogenesis and vascularization in 510 CAF: 231 co-injection tumors
compared to controls.
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Future Direction
Next steps in this project will be to continue to investigate the racial disparity of miR-510 and
Cav-1 expression in breast cancer patients. Our preliminary data have established in a cohort of
breast cancer serum samples that miR-510 levels are elevated in AA women when compared to
their benign counterparts, but tissue expression of miR-510 and CAV1 will show if a negative
correlation exists in patients. In collaboration with SCSU, our lab will continue to add data from
patient samples. Based on our hypothesis, we expect to see an inverse correlation between miR510 and Cav-1 in both the AA and CA samples. However, we expect to see higher miR-510 and
lower Cav-1 levels overall in the AA samples or a greater number of patients with the inverse
correlation in the AA group of patients. We may also expect to see higher miR-510 levels in the
CAFs within the stroma of these tissue samples. In-situ hybridization of miR-510 will allow us to
examine its expression in specific tumor cell populations (stromal/epithelial). The results
generated so far have provided encouraging evidence and collaboration with Dr. Evans-Knowell
will help determine the role of miR-510 in promoting stromal loss of Cav-1and its implications in
breast cancer disparity.

While we are confident that we have identified a potential biological mechanistic link driving
stromal Cav-1 loss and worse outcome in AA breast cancer patients, we are unsure of how miR510 is transferring to stromal cells from epithelial cancer cells. Our greatest challenge moving
forward will be to determine in which microvesicle miR-510 is transferred. We must also explore
the alternative hypothesis that a growth factor or released cytokine is upregulating miR-510
expression. Therefore, we must consider exploring the role of miR-510 on various pathways,
including VEGF or TFGβ1/2.
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Study Significance
The goal of this project is to provide novel insight into racial specific cancer associated miR-510
and Cav-1 expression levels in breast cancer that could lead to more effective individualized
screening and treatment options. Tumor-derived microvesicles that result in circulating miRNAs
in the blood may even be able to serve as accessible biomarkers for diagnosis and prognosis.
This project could have a significant impact on the development of novel strategies for the racial
specific treatment of breast cancer, thereby decreasing the gap in breast cancer mortality rates
between AA women and CA women. By exploring its role in regulation of stromal Cav-1, miR510 may provide a novel pathway that is driving the racial disparity in breast cancer. Future
studies could assess the utilization of miR-510 as a therapeutic target, preventing the loss of
stromal Cav-1 and thereby improving breast cancer prognosis. This research has great
translational significance, providing a potential means to reduce racial disparity in breast cancer
and to help relieve the burden of this disease, specifically in the AA community.
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